Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

New England Journal of Medicine

Volumn 368, Issue 20, 2013, Pages 1867-1877

  Jacobson, Ira M ^a   Gordon, Stuart C ^b   Kowdley, Kris V ^c   Yoshida, Eric M ^d   Rodriguez Torres, Maribel ^f   Sulkowski, Mark S ^g   Shiffman, Mitchell L ^h   Lawitz, Eric ⁱ   Everson, Gregory ^k   Bennett, Michael ^l   Schiff, Eugene ⁿ   Al Assi, M Tarek ^j   Subramanian, G Mani ^m   An, Di ^m   Lin, Ming ^m   McNally, John ^m   Brainard, Diana ^m   Symonds, William T ^m   McHutchison, John G ^m   Patel, Keyur ^p   Feld, Jordan ^e   Pianko, Stephen ^q   Nelson, David R ^o   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Henry Ford Health Systems   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f Department of Hematology and Oncology   (Puerto Rico)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Bon Secours Health System   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j Texas Digestive Disease Consultants   (United States)

^k UNIVERSITY OF COLORADO   (United States)

^l Medical Associates Research Group   (United States)

^m GILEAD SCIENCES   (United States)

ⁿ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF FLORIDA   (United States)

^p DUKE UNIVERSITY   (United States)

^q MONASH MEDICAL CENTRE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PLACEBO; RIBAVIRIN; SOFOSBUVIR;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; IRRITABILITY; LEUKOCYTE COUNT; LIVER CIRRHOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VIROLOGY;

EID: 84877739274     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1214854     Document Type: Article

References (14)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
2. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34. (Pubitemid 47057730)
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
4. Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009;136:1618-28.
5. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-92. (Pubitemid 34150758)
6. Sulkowski MS, Cooper C, Hunyady B, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011;8:212-23.
7. Lam AM, Murakami E, Espiritu C, et al. PSI-7851, a pronucleotide of beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother 2010;54:3187-96.
8. Gane EJ, Stedman CA, Hyland RH, et al. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: the ELECTRON trial. Hepatology 2012;56:Suppl:306A-307A. abstract.
9. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44.
10. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′→3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A 1991;88:7276-80. (Pubitemid 21915133)
11. Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Pract Res Clin Gastroenterol 2010;24:183-92.
12. Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012;56:2039-50.
13. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013. DOI: 10.1056/NEJMoa1214853.
14. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92. (Pubitemid 28543496)